États-Unis · Bourse & Finance · MarketWatch

Alector Enters Licensing Agreement With Genentech for Parkinson's Therapy

Publié par MarketWatch · États-Unis il y a 9 h

Alector entered into an exclusive global licensing agreement with Genetech, which will receive worldwide rights to develop and commercialize Alector's AL050 program.

Lire l'article complet sur MarketWatch Connectez-vous pour sauvegarder

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.marketwatch.com)

Alector Enters Licensing Agreement With Genentech for Parkinson's Therapy

À lire aussi

Rubio Opens 4-Day NATO Tour in Iceland to Discuss Arctic Security

The final Disrupt Stage lineup: Three days of conversations you won’t hear anywhere outside of TechCrunch Disrupt 2026

Half of bond ETFs now show negative one-year returns

My partner and I always thought we agreed on money. Then, we moved in together.

Metaplanet reveals net income strategy to fuel Bitcoin accumulation

Stripe to expand stablecoin cards to over 100 countries by the end of the year

Alector Enters Licensing Agreement With Genentech for Parkinson's Therapy

Partager

À lire aussi

Rubio Opens 4-Day NATO Tour in Iceland to Discuss Arctic Security

The final Disrupt Stage lineup: Three days of conversations you won’t hear anywhere outside of TechCrunch Disrupt 2026

Half of bond ETFs now show negative one-year returns

My partner and I always thought we agreed on money. Then, we moved in together.

Metaplanet reveals net income strategy to fuel Bitcoin accumulation

Stripe to expand stablecoin cards to over 100 countries by the end of the year